Intercept's drug for patients with liver fibrosis due to NASH meets main goal

Intercept Pharmaceuticals Inc said on Tuesday its treatment testing patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH) met the main goal in a late-stage study.